ICIsabella Cavagna

Isabella Cavagna

*This is an algorithmically generated author record based on publicly available information.

Isabella Cavagna has a total of 17 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Cell-Free DNA Profiles End-Organ Injury and Predicts Outcomes in Advanced Heart Failure With Left Ventricular Assist Device Implantation

    by Ashley Park, Temesgen E. Andargie, Xin Tian, Michael Keller, Isabella Cavagna, Neelam Redekar, Tom Hill, Hyesik Kong, Woojin Park, Xinyue Zhao, et al.

    BACKGROUND: Adverse events after durable left ventricular assist devices (LVADs) pose a challenge to survival. However, there are limited risk stratification approaches. Plasma cell-free DNA (cfDNA) offers potential as a biomarker for assessing end-organ injury and risk stratification. METHODS: The study included a multicenter prospective cohort of patients with heart failure with and without LVAD (cohort 1), a separate cohort of patients with heart failure with paired samples before and after LVAD (cohort 2) implantation, and a comparator group of healthy controls. Nuclear cfDNA (ncfDNA) and mitochondrial cfDNA were quantified by digital droplet polymerase chain reaction. Tissue-specific cfDNA was identified using whole-genome bisulfite sequencing. Differences in cfDNA levels by LVAD use were assessed with the Wilcoxon rank-sum test or the paired t test. Outcomes (hemocompatibility-related adverse event–free survival and infection-free survival) by cfDNA tertiles were compared by log-rank tests. RESULTS: Cohort 1 had 76 patients with LVAD and 144 without LVAD. Cohort 2 had 40 patients with LVAD with samples before and after LVAD. ncfDNA levels were 4-fold higher (9794 versus 2386 copies/mL; P P =0.01) in cohort 1 compared with healthy controls (n=48). Patients without LVAD had higher ncfDNA levels compared with those with LVAD in cohort 1 (11 423 versus 7912 copies/mL; P =0.019). After LVAD placement in cohort 2, ncfDNA nearly halved (18 980 versus 10 228 copies/mL; P P =0.006) and hemocompatibility-related adverse event–free (hazard ratio, 3.24 [95% CI, 1.03–10.3]; P =0.034) survival. CONCLUSIONS: LVAD implantation was associated with reductions in systemic and tissue-specific cfDNA levels. cfDNA levels offer promise for improving risk stratification of LVAD candidates for post-LVAD outcomes.